SG10201803999UA - Recombinant factor viii formulations - Google Patents

Recombinant factor viii formulations

Info

Publication number
SG10201803999UA
SG10201803999UA SG10201803999UA SG10201803999UA SG10201803999UA SG 10201803999U A SG10201803999U A SG 10201803999UA SG 10201803999U A SG10201803999U A SG 10201803999UA SG 10201803999U A SG10201803999U A SG 10201803999UA SG 10201803999U A SG10201803999U A SG 10201803999UA
Authority
SG
Singapore
Prior art keywords
factor viii
recombinant factor
formulations
viii formulations
recombinant
Prior art date
Application number
SG10201803999UA
Other languages
English (en)
Inventor
De Qian Wang
Xinghang Ma
Nelly Tsvetkova
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SG10201803999UA publication Critical patent/SG10201803999UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201803999UA 2013-03-15 2014-03-11 Recombinant factor viii formulations SG10201803999UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15
US201361869191P 2013-08-23 2013-08-23

Publications (1)

Publication Number Publication Date
SG10201803999UA true SG10201803999UA (en) 2018-06-28

Family

ID=51580768

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201803999UA SG10201803999UA (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations
SG11201507618YA SG11201507618YA (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201507618YA SG11201507618YA (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Country Status (17)

Country Link
US (1) US20160030524A1 (https=)
EP (1) EP2970430A4 (https=)
JP (1) JP2016518321A (https=)
KR (1) KR20150132449A (https=)
CN (1) CN105209487A (https=)
AU (1) AU2014237111B2 (https=)
BR (1) BR112015022730A2 (https=)
CA (1) CA2905739A1 (https=)
HK (1) HK1213273A1 (https=)
MX (1) MX2015012905A (https=)
PE (1) PE20160121A1 (https=)
RU (1) RU2015144076A (https=)
SG (2) SG10201803999UA (https=)
TW (1) TW201521761A (https=)
UY (1) UY35412A (https=)
WO (1) WO2014150477A1 (https=)
ZA (1) ZA201507684B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190064147A1 (en) * 2015-01-18 2019-02-28 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
EA202190827A1 (ru) 2015-11-13 2021-11-30 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
US12091675B2 (en) 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
US20220305089A1 (en) * 2019-08-16 2022-09-29 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
KR20010101901A (ko) * 1999-02-01 2001-11-15 모리 데쯔지 음극선관 및 그 제조방법
DK1820516T3 (da) * 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
ES2331909T3 (es) * 2001-06-14 2010-01-20 The Scripps Research Institute Factor viii estabilizado con enlaces disulfuro modificados geneticamente.
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
AU2007245190B2 (en) * 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
MX339060B (es) * 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety

Also Published As

Publication number Publication date
BR112015022730A2 (pt) 2017-10-31
AU2014237111B2 (en) 2018-06-21
PE20160121A1 (es) 2016-03-03
EP2970430A4 (en) 2017-01-11
US20160030524A1 (en) 2016-02-04
AU2014237111A1 (en) 2015-10-08
EP2970430A1 (en) 2016-01-20
CN105209487A (zh) 2015-12-30
MX2015012905A (es) 2016-06-16
HK1213273A1 (zh) 2016-06-30
ZA201507684B (en) 2017-06-28
JP2016518321A (ja) 2016-06-23
CA2905739A1 (en) 2014-09-25
SG11201507618YA (en) 2015-10-29
RU2015144076A (ru) 2017-04-24
UY35412A (es) 2014-10-31
WO2014150477A1 (en) 2014-09-25
TW201521761A (zh) 2015-06-16
KR20150132449A (ko) 2015-11-25

Similar Documents

Publication Publication Date Title
MY191035A (en) Affinity-oligonucleotide conjugates and uses thereof
PH12016500316A1 (en) Improved adenovirus formulations
MX2016007063A (es) Peptidos terapeuticos.
IL238130B (en) Modified recombinant viruses containing the pr13.5 promoter and their uses
MX2021012014A (es) Vectores del factor viii del virus adeno-asociado.
SG10201803042PA (en) Anti-tim-3 antibodies
EP3736282C0 (en) CELL-PERFORMING PEPTIDE, CONJUGATE THEREOF AND COMPOSITION WITH THE CONJUGATE
EP3043820A4 (en) Methods and compositions comprising purified recombinant polypeptides
MX357202B (es) Composicion de particula tipo virus.
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
PH12013502671A1 (en) Glucagon/glp-1 receptor co-agonists
IL236315A (en) Compositions comprising purified recombinant iduronate-2-sulfatase
MX2015008065A (es) Composiciones pesticidas y procesos relacionados con ellas.
EP2981543A4 (en) Novel 4 7 peptide antagonists
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
SG11201505924TA (en) Factor viii polypeptide formulations
SG10201803370XA (en) Conjugates of somatostatin and its analogs
WO2013123046A3 (en) Cathode buffer materials and related devices and methods
MX349485B (es) Composiciones de higiene bucal.
SG10201803999UA (en) Recombinant factor viii formulations
PT2899198T (pt) Péptido sintético pntx(19), composições farmacêuticas e utilização
EP3052526A4 (en) Recombinant polypeptides comprising mhc class ii 1 domains
MX2015011053A (es) Composiciones de higiene bucal.
AR095431A1 (es) Formulaciones de fviii recombinante
UA90689U (uk) Комплексний протипаразитарний препарат "лактоверм"